BUSINESSJun 22 · 21:20 UTCTHE RIO TIMESRichard Mann

America’s Split Economy: The Boom and the Worker

AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion in a debt-funded deal, offering a 49% premium over Apogee’s June 18 closing share price. The transaction reflects a long-term investment in the company’s future growth.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

AbbVieorganizationApogee TherapeuticsorganizationUniversity oforganization

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSApr 24 · 17:32 UTC
Ethereum news: Bitmine (BMNR) to buy 10,000 ETH for $23.8M from Ethereum Foundation
BUSINESSJun 9 · 07:14 UTC
GSK Agrees to Buy Nuvalent for $10.6 Billion
BUSINESSJun 22 · 11:45 UTC
STAT+: AbbVie to buy Apogee Therapeutics in nearly $11B deal
BUSINESSJun 9 · 01:25 UTC
GSK in Talks to Buy Nuvalent for More Than $9 Billion: FT
BUSINESSApr 23 · 17:09 UTC
Warner Bros. Shareholders Approve $110 Billion Paramount Deal
BUSINESSJun 9 · 06:48 UTC
STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B